Revenue experienced a catastrophic contraction to $22.8K in 2026Q1, driving gross margins into a deep negative territory of -99.5%.
| Sales/Revenue | 5.31M | 7.42M | 9.51M | 9.77M | 10.93M | 13.36M | 11.39M | 126.95K | 212.33K | 107.68K | 0 |
| Revenue Growth % | -42.69% | -21.93% | -2.66% | -10.6% | -18.21% | 17.31% | 8872.03% | -40.21% | 97.18% | - | - |
| Cost of Goods Sold | 4.59M | 6.34M | 8.22M | 8.44M | 9.67M | 11.17M | 9.67M | 71.07K | 183.56K | 28.87K | 0 |
| COGS % of Revenue | - | 85.38% | 86.44% | 86.39% | 88.48% | 83.58% | 84.9% | 55.98% | 86.45% | 26.81% | - |
| Gross Profit | 718.99K | 1.09M | 1.29M | 1.33M | 1.26M | 2.19M | 1.72M | 55.89K | 28.77K | 78.81K | 0 |
| Gross Margin % | 13.54% | 14.62% | 13.56% | 13.61% | 11.52% | 16.42% | 15.1% | 44.02% | 13.55% | 73.19% | - |
| Gross Profit Growth % | - | -15.84% | -3.01% | 5.6% | -42.61% | 27.56% | 2977.27% | 94.29% | -63.5% | - | - |
| Operating Expenses | 3.64M | 4.24M | 2.86M | 3.92M | 1.55M | 1.14M | 446K | 331.59K | -31.14K | 206.72K | 835 |
| OpEx % of Revenue | - | 57.15% | 30.11% | 40.15% | 14.18% | 8.52% | 3.92% | 261.19% | -14.66% | 191.97% | - |
| Selling, General & Admin | 2.57M | 4.07M | 4M | 3.04M | 1.73M | 1.2M | 1.33M | 356.64K | 241.93K | 206.72K | 835 |
| SG&A % of Revenue | - | 54.77% | 42.11% | 31.11% | 15.83% | 9.01% | 11.7% | 280.92% | 113.94% | 191.97% | - |
| Research & Development | 53.02K | 50.67K | 47.51K | 54.98K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 0.68% | 0.5% | 0.56% | - | - | - | - | - | - | - |
| Other Operating Expenses | 846.95K | 126.44K | -1.19M | 828.39K | -179.28K | -66.49K | -886.94K | -25.05K | -273.07K | 0 | 0 |
| Operating Income | -2.92M | -3.16M | -1.57M | -2.59M | -291.18K | 1.06M | 1.27M | -275.7K | 59.9K | -127.91K | -840 |
| Operating Margin % | -54.93% | -42.54% | -16.55% | -26.54% | -2.66% | 7.9% | 11.18% | -217.17% | 28.21% | -118.79% | - |
| Operating Income Growth % | - | -100.7% | 39.32% | -790.73% | -127.58% | -17.11% | 562.02% | -560.27% | 146.83% | -15127.38% | - |
| EBITDA | -2.75M | -2.99M | -1.42M | -2.49M | -185.76K | 1.16M | 1.38M | -222.37K | 100.51K | -112.88K | -5 |
| EBITDA Margin % | -51.69% | -40.27% | -14.94% | -25.43% | -1.7% | 8.71% | 12.08% | -175.16% | 47.34% | -104.83% | - |
| EBITDA Growth % | -40.81% | -110.49% | 42.84% | -1237.85% | -115.96% | -15.37% | 718.52% | -321.24% | 189.04% | -2257480% | - |
| D&A (Non-Cash Add-back) | 172.17K | 168.31K | 153.14K | 108.42K | 105.42K | 108.22K | 101.6K | 53.33K | 40.61K | 15.03K | 835 |
| EBIT | -2.89M | -2.97M | -1.57M | -2.59M | -291.18K | 1.06M | 1.27M | -275.7K | 59.9K | -119.42K | -835 |
| Net Interest Income | 66.26K | 64.35K | 126.5K | -13.93K | -12.48K | -12.97K | -11.31K | 0 | 0 | 0 | 0 |
| Interest Income | 77.5K | 83.89K | 147.64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 11.24K | 19.54K | 21.15K | 13.93K | 12.48K | 12.97K | 11.31K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 12.38K | 173.84K | -21.15K | -13.93K | -12.48K | -12.97K | -11.31K | 0 | 0 | 0 | 5 |
| Pretax Income | -2.9M | -2.98M | -1.59M | -2.61M | -303.66K | 1.04M | 1.26M | -275.7K | 59.9K | -119.41K | -835 |
| Pretax Margin % | -54.7% | -40.2% | -16.77% | -26.69% | -2.78% | 7.8% | 11.08% | -217.17% | 28.21% | -110.9% | - |
| Income Tax | 0 | 0 | 3.49K | 21.53K | 52.31K | 291.28K | 168.41K | -29.24K | 33.45K | 4.34K | 0 |
| Effective Tax Rate % | 0% | 0% | -0.22% | -0.83% | -17.23% | 27.93% | 13.34% | 10.6% | 55.84% | -3.63% | 0% |
| Net Income | -2.9M | -2.98M | -1.6M | -2.63M | -355.97K | 751.57K | 1.09M | -246.47K | 26.45K | -123.75K | -835 |
| Net Margin % | -54.7% | -40.2% | -16.81% | -26.91% | -3.26% | 5.62% | 9.61% | -194.14% | 12.46% | -114.92% | - |
| Net Income Growth % | -37.16% | -86.73% | 39.2% | -638.57% | -147.36% | -31.31% | 543.91% | -1031.69% | 121.38% | -14720.36% | - |
| Net Income (Continuing) | -2.9M | -2.98M | -1.6M | -2.63M | -355.97K | 751.57K | 1.09M | -246.47K | 26.45K | -123.75K | -835 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.20 | -1.61 | -0.90 | -1.53 | -0.25 | 0.53 | 1.28 | -0.03 | 0.00 | -0.02 | -0.00 |
| EPS Growth % | -25.42% | -78.89% | 41.18% | -512% | -147.17% | -58.59% | 3842.69% | - | 124.12% | - | - |
| EPS (Basic) | - | -1.61 | -0.90 | -1.53 | -0.25 | 0.53 | 1.28 | -0.03 | 0.00 | -0.02 | -0.00 |
| Diluted Shares Outstanding | 2.42M | 1.86M | 1.78M | 1.72M | 1.44M | 1.43M | 857.65K | 719.74K | 552.8K | 621.9K | 621.9K |
| Basic Shares Outstanding | 2.42M | 1.86M | 1.78M | 1.72M | 1.44M | 1.43M | 857.65K | 719.74K | 552.8K | 621.9K | 621.9K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and operational viability
According to the most recent quarterly financial data, BGLC experienced a catastrophic revenue decline to $22.8K in 2026Q1, representing a near-total erosion of the top line compared to historical quarterly averages that previously hovered in the $2.0M to $2.6M range for the prior two years.
The precipitous drop in revenue suggests that the core chemical distribution business may have effectively ceased operations or lost its primary customer base. This trend indicates that the company's pivot toward diagnostic services has failed to provide a meaningful revenue floor, leaving the firm with negligible top-line momentum.
As reported in the company's income statements, gross margins have collapsed into negative territory at -99.5% in 2026Q1, a stark departure from the 14.62% average observed in more stable periods, indicating a complete loss of pricing power and inability to cover basic procurement costs.
The negative gross margin implies that the cost of goods sold now exceeds the revenue generated, which is highly unusual for a distribution-based business model. This suggests that the company may be liquidating inventory at a loss or facing severe supply chain inefficiencies that render the current business model unsustainable.
Based on the provided financial filings, BGLC's operating margin plummeted to -25.0% in 2026Q1, reflecting a failure to scale fixed costs against a shrinking revenue base, which has effectively neutralized any potential for operational leverage within the current organizational structure.
The inability to reduce SG&A expenses in proportion to the massive revenue decline suggests a rigid cost structure that is ill-suited for the current scale of operations. Investors should monitor whether the company can implement drastic cost-cutting measures to prevent further depletion of its remaining cash reserves.
Financial data suggests that BGLC's valuation may be disconnected from its operational reality, as the company is currently burning through its $2.38 million cash position while maintaining a cost structure that appears incompatible with its current, severely diminished revenue-generating capacity.
Short-sellers would likely focus on the discrepancy between the company's 'Gene Lab' branding and the reality of its failing chemical distribution business. The lack of a clear path to profitability, combined with the recent revenue collapse, warrants significant skepticism regarding the company's long-term survival without external capital injection.
Quick answers to the most common questions about buying BGLC stock.
For fiscal year 2025, BioNexus Gene Lab Corp. (BGLC) reported total revenue of $7.4M.
BioNexus Gene Lab Corp. (BGLC) reported a net loss of $3.0M for the fiscal year ending 2025.
BioNexus Gene Lab Corp. (BGLC) reported an operating income of $-3.2M, resulting in an operating profit margin of -42.5%. This margin reflects the operational efficiency of the business before interest and taxes.
BioNexus Gene Lab Corp. (BGLC) generated $1.1M in gross profit for the year, representing a gross profit margin of 14.6%. This demonstrates the company's core pricing power and production efficiency.